AR040021A1 - (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacion - Google Patents

(s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacion

Info

Publication number
AR040021A1
AR040021A1 ARP030101702A ARP030101702A AR040021A1 AR 040021 A1 AR040021 A1 AR 040021A1 AR P030101702 A ARP030101702 A AR P030101702A AR P030101702 A ARP030101702 A AR P030101702A AR 040021 A1 AR040021 A1 AR 040021A1
Authority
AR
Argentina
Prior art keywords
preparation
chloro
amino
pharmaceutical composition
tetrahidrofuril
Prior art date
Application number
ARP030101702A
Other languages
English (en)
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of AR040021A1 publication Critical patent/AR040021A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe el compuesto (S)-4-amino-5-cloro-2-metoxi-N-[1-[1-(2-tetrahidrofurilcarbonil)-4-piperidinilmetil]-4-piperidinil]benzamida de la siguiente fórmula (1), o una sal de adición de un ácido farmacéuticamente aceptable, o un hidrato de ésta. Dicho compuesto es útil como mejorador de la motilidad gastrointestinal o como agente procinético gastrointestinal, que manifiesta una potente afinidad por el receptor 5-HT4 y presenta poco efecto sobre el corazón y además presenta pocos efectos secundarios en el sistema nervioso central, basados en el receptor de dopamina D2. También se describen un procedimiento para preparar el compuesto, una composición farmacéutica que lo contiene y un intermediario para ese fin.
ARP030101702A 2002-05-16 2003-05-15 (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacion AR040021A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002141262 2002-05-16

Publications (1)

Publication Number Publication Date
AR040021A1 true AR040021A1 (es) 2005-03-09

Family

ID=29267809

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101702A AR040021A1 (es) 2002-05-16 2003-05-15 (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacion

Country Status (27)

Country Link
US (1) US6696468B2 (es)
EP (1) EP1362857B1 (es)
JP (1) JP3643107B2 (es)
KR (1) KR20040107520A (es)
CN (1) CN1653063A (es)
AR (1) AR040021A1 (es)
AT (1) ATE273304T1 (es)
AU (1) AU2003230245A1 (es)
BR (1) BR0309933A (es)
CA (1) CA2483368A1 (es)
CZ (1) CZ20041084A3 (es)
DE (1) DE60300021T2 (es)
DK (1) DK1362857T3 (es)
ES (1) ES2227500T3 (es)
HK (1) HK1060118A1 (es)
HU (1) HUP0501016A2 (es)
IL (1) IL165012A0 (es)
MX (1) MXPA04011332A (es)
NO (1) NO20045469L (es)
PL (1) PL372724A1 (es)
PT (1) PT1362857E (es)
RU (1) RU2004136853A (es)
SK (1) SK50192004A3 (es)
TR (1) TR200403020T2 (es)
TW (1) TW200400186A (es)
WO (1) WO2003097638A1 (es)
ZA (1) ZA200409053B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
JP5042028B2 (ja) * 2004-11-05 2012-10-03 セラヴァンス, インコーポレーテッド キノリノン−カルボキサミド化合物
US7419989B2 (en) * 2004-12-22 2008-09-02 Theravance, Inc. Indazole-carboxamide compounds
EP1871772B1 (en) * 2005-03-02 2014-09-10 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US7256294B2 (en) * 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound
WO2006126948A1 (en) * 2005-05-27 2006-11-30 Astrazeneca Ab Piperidines for the treatment of chemokine mediated diseases
TW200722419A (en) * 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
EP1912941B1 (en) 2005-07-21 2012-11-14 AstraZeneca AB Piperidine derivatives
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
TWI423967B (zh) * 2008-02-21 2014-01-21 Dainippon Sumitomo Pharma Co 醯胺衍生物及含有其之醫藥組合物
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH111472A (ja) 1996-04-30 1999-01-06 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体及びそれを含有する医薬組成物
HUP0101511A3 (en) * 1998-04-28 2002-12-28 Dainippon Pharmaceutical Co 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
JP2000080081A (ja) 1998-06-24 2000-03-21 Dainippon Pharmaceut Co Ltd 1―〔(1―置換―4―ピペリジニル)メチル〕―4―ピペリジン誘導体及びそれを含有する医薬組成物
JP2001122784A (ja) 1999-10-27 2001-05-08 Dainippon Pharmaceut Co Ltd 1−[(1−置換−4−ピペリジニル)メチル]−4−ピペリジン誘導体からなる医薬

Also Published As

Publication number Publication date
ATE273304T1 (de) 2004-08-15
ES2227500T3 (es) 2005-04-01
CA2483368A1 (en) 2003-11-27
PT1362857E (pt) 2004-11-30
US20030216433A1 (en) 2003-11-20
JP2004043453A (ja) 2004-02-12
BR0309933A (pt) 2005-02-09
US6696468B2 (en) 2004-02-24
DK1362857T3 (da) 2004-12-20
TR200403020T2 (tr) 2005-05-23
RU2004136853A (ru) 2005-06-27
DE60300021D1 (de) 2004-09-16
EP1362857B1 (en) 2004-08-11
IL165012A0 (en) 2005-12-18
WO2003097638A1 (en) 2003-11-27
ZA200409053B (en) 2005-07-12
HUP0501016A2 (en) 2006-02-28
HK1060118A1 (en) 2004-07-30
MXPA04011332A (es) 2005-02-14
NO20045469L (no) 2005-02-16
DE60300021T2 (de) 2005-09-08
SK50192004A3 (sk) 2005-04-01
EP1362857A1 (en) 2003-11-19
JP3643107B2 (ja) 2005-04-27
KR20040107520A (ko) 2004-12-20
AU2003230245A1 (en) 2003-12-02
CZ20041084A3 (cs) 2005-02-16
PL372724A1 (en) 2005-07-25
TW200400186A (en) 2004-01-01
CN1653063A (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
AR040021A1 (es) (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacion
DK1675591T3 (da) Farmaceutisk sammensætning omfattende en monoamin-neurotransmitter-genoptagelseshæmmer og en acetylcholinesterase-hæmmer
PA8591701A1 (es) Derivados de pirrolopirimidina
BR0312975A (pt) Forma cristalina de agonista de receptor adrenérgico ß2
WO2004106279A3 (en) CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
PE20070521A1 (es) 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
NO20075920L (no) Assosiasjon mellom ferroquin og et artemisininderivat for behandling av malaria
NO20064240L (no) Farmasoytiske forbindelser for oral administrasjon og fremgangsmate for fremstilling derav
AR029942A1 (es) Compuestos derivados de 1,3-dihidro-2h-indol-2-ona, su utilizacion, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden, medicamentos constituidos por dichos compuestos y compuestos intermediarios
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos
ATE386725T1 (de) Heterocyclylverbindungen
AR004158A1 (es) Compuesto de ftalizin-pirido dionas; composición farmacéutica que lo contiene; y proceso para la preparación de dicho compuesto.
DE60217843D1 (de) Ein dioxinoä2,3-güchinolin-9-carbonsäure derivat als nk3 rezeptor antagonist
DE602004024383D1 (de) Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists
ATE318266T1 (de) 3-substituierte chinolin-4- carbonsäureamidderivate als nk-3- und nk-2- rezeptorantagonisten
PE20040767A1 (es) Derivado hemisulfato de azido citosina cristalino anhidro
CA2406266A1 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
NO980333L (no) (R)-5-brom-N-(1-etyl-4-metylheksahydro-1H-1,4-diazepin-6-yl)-2-metoksy-6-metylamino-3-pyridinkarboksamid, fremgangsmåte ved fremstilling derav og farmasöytisk sammensetning inneholdende forbindelsen
DE60214830D1 (de) C2,8-disubstituierte adenosinderivate und ihre verschiedenen verwendungen
UY38055A (es) Composiciones oftálmicas de compuestos de bencimidazol para uso unico diario
BR0210063A (pt) Composição estável e uso da mesma

Legal Events

Date Code Title Description
FB Suspension of granting procedure